,,ii #aagth ,,congress #b;d ,session ,s4 #dcij ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,june #ad1 #bjbb,mr4 ,hickenlooper introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to require summary approval information with respect to certain approved drugs and biological products4 #a4 ,short title ,this ,act may be cited as the ,accelerated ,approval ,transparency ,act4 #b4 ,summary approval information ,with respect to each new drug application for a new molecular entity approved under section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;c77 or biological product licensed under section #cea7;a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;a77 pursuant to accelerated approval under section #ejf7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7;c771 the ,secretary of ,health and ,human ,services shall provide for the drug or biologic action package a summary of the basis for approval1 including1 as relates to such new molecular entity1 whether an advisory committee meeting was held and a rationale for a determination by the ,secretary that a surrogate endpoint is reasonably likely to predict clinical benefit4